Abstracts tagged "Health care cost and systemic lupus erythematosus (SLE)"

Abstract Number: 195 • 2017 ACR/ARHP Annual Meeting
Health Care Costs of Patients with Systemic Lupus Erythematosus (SLE) Versus Control Patients As a Function of Disease Severity: Analysis of the Betriebskrankenkassen German Sickness Fund
Edward R. Hammond¹, Heiko Friedel², Elena Garal-Pantaler², Marc Pignot³, Erica Velthuis⁴, Xia Wang¹, Henk Nab⁵, Barnabas Desta¹ and Andreas Schwarting⁶, ¹AstraZeneca, Gaithersburg, MD, ²Team Gesundheit GmbH, Essen, Germany, ³Kantar Health GmbH, Munich, Germany, ⁴Evidera PPD, Utrecht Area, Netherlands, ⁵AstraZeneca, Cambridge, United Kingdom, ⁶Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
Background/Purpose: SLE is a chronic, debilitating, multisystem autoimmune disorder of connective tissue. In developing new treatment options, the economic burden of SLE should be quantified…
Abstract Number: 207 • 2017 ACR/ARHP Annual Meeting
Direct Medical Costs of Systemic Lupus Erythematosus in South Korea
So-Yeon Park¹ and Sang-Cheol Bae², ¹Department of Rhematology, Myongji Hospital, Seonam university, Goyang, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Systemic lupus erythematosus (SLE) has very high economic burdens on society and healthcare system. The aim of this study was to estimate the annual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].